Microsomal Protein Concentration Modifies the Apparent Inhibitory Potency of CYP3A Inhibitors-Reference-Cited by-同舟云学术

Microsomal Protein Concentration Modifies the Apparent Inhibitory Potency of CYP3A Inhibitors

Published:2002-12-01 Issue:12 Volume:30 Page:1441-1445
ISSN:0090-9556
Container-title:Drug Metabolism and Disposition
language:en
Short-container-title:Drug Metab Dispos

Author:

Tran Thanh Huu,von Moltke Lisa L.,Venkatakrishnan Karthik,Granda Brian W.,Gibbs Megan A.,Obach R. Scott,Harmatz Jerold S.,Greenblatt David J.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmaceutical Science,Pharmacology

Reference31 articles.

1. Diazepam metabolism by human liver microsomes is mediated by both S- mephenytoin hydroxylase and CYP3A isoforms.

2. Erve JCL Dandeneau AA Patten C Stresser DM Crespi CL (2000) Metabolic stability of CYP isoform selective inhibitors in the presence of human liver microsomes. 13th International Symposium on Microsomes and Drug Oxidation, Stressa, Italy.

3. In vitro forecasting of drugs which may interfere with the biotransformation of midazolam

4. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human and cDNA-expressed human cytochrome P450.;Ghosal;Drug Metab Dispos,1996

5. Effect of inhibitor depletion on inhibitory potency: tight binding inhibition of CYP3A by clotrimazole.;Gibbs;Drug Metab Dispos,1999

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Defining the Selectivity of Chemical Inhibitors Used for Cytochrome P450 Reaction Phenotyping: Overcoming Selectivity Limitations with a Six-Parameter Inhibition Curve-Fitting Approach;Drug Metabolism and Disposition;2022-07-01

2. Evaluation of the effects of four types of tea on the activity of cytochrome P450 enzymes with a probe cocktail and HPLC-MS/MS;Annals of Translational Medicine;2022-05

3. HLM-beads: Rapid Assessment of Nonspecific Binding to Human Liver Microsomes Using Magnetizable Beads;Drug Metabolism and Disposition;2021-09-24

4. Evaluation of Drug‐Drug Interaction Liability for Buprenorphine Extended‐Release Monthly Injection Administered by Subcutaneous Route;Clinical Pharmacology in Drug Development;2021-03-22

5. Case Study 5: Predicting the Drug Interaction Potential for Inhibition of CYP2C8 by Montelukast;Methods in Molecular Biology;2021